Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib Long-term Safety in Moderate to Severe Crohn's Disease
CTR20220454Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in Crohn's disease, sponsored by Bristol Myers Squibb. Started Mar 2022; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20220454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220454.